Advertisement

Current Oncology Reports

, 21:16 | Cite as

New Treatment Options for Acute Myeloid Leukemia in 2019

  • Marco Cerrano
  • Raphael ItzyksonEmail author
Leukemia (A Aguayo, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Leukemia

Abstract

Purpose of Review

The extensive genomic characterization of acute myeloid leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We review relevant data that have led to recent approval of new targeted therapies in AML and discuss the most promising drugs currently in development in this disease.

Recent Findings

New formulations of cytotoxic agents, namely CPX-351 and gemtuzumab ozogamicin, improve the outcome of defined subgroup of patients. Midostaurin added to intensive chemotherapy is approved in FLT3-mutated AML. More selective FLT3 inhibitors and the IDH inhibitors enasidenib and ivosidenib have shown significant single agent activity in the relapsed setting, and preliminary results of combination strategies are encouraging. The addition of the BCL2 inhibitor venetoclax appears to markedly improve the results of hypomethylating agents.

Summary

The therapeutic armamentarium of AML now includes novel cytotoxic drugs, drugs targeting recurrent oncogenes, or functional vulnerabilities of leukemic cells. Further work is required to optimize their integration to the current framework of AML management, including allogeneic stem cell transplantation.

Keywords

Acute myeloid leukemia Targeted therapy FLT3 inhibitors BCL2 inhibitors IDH inhibitors Hypomethylating agents 

Notes

Compliance with Ethical Standards

Conflict of Interest

Marco Cerrano declares that he has no conflict of interest.

Raphael Itzykson has received research funding from Oncoethix S.A. (now Merck), Janssen and Novartis; has received consulting fees from Jazz Pharmaceuticals, Otsuka, and Karyopharm Therapeutics; has received honoraria from Bristol-Myers Squibb, Celgene, and Sanofi; and has received travel grants from Daiichi Sankyo.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.  https://doi.org/10.1182/blood-2016-03-643544.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.  https://doi.org/10.1056/NEJMoa1301689.CrossRefGoogle Scholar
  3. 3.
    Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.  https://doi.org/10.1056/NEJMoa1516192.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35:934–46.  https://doi.org/10.1200/JCO.2016.71.2208.CrossRefPubMedGoogle Scholar
  5. 5.
    Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593–606.  https://doi.org/10.1016/S0140-6736(18)31041-9.CrossRefPubMedGoogle Scholar
  6. 6.
    Michaelis LC, Klepin HD, Walter RB. Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. Expert Opin Pharmacother. 2018;19:865–82.  https://doi.org/10.1080/14656566.2018.1465562.CrossRefPubMedGoogle Scholar
  7. 7.
    Dombret H, Itzykson R. How and when to decide between epigenetic therapy and chemotherapy in patients with AML. Hematology Am Soc Hematol Educ Program. 2017;2017:45–53.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53–61.  https://doi.org/10.1182/blood-2015-08-604520.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Crisà E, Cerrano M, Gatti T, Giai V, Aguzzi C, Boccadoro M, et al. The combination of fludarabine + citarabine + idarubicin (FLAI), followed by post-remission maintenance, is a safe and effective treatment for elderly patients with AML or high risk MDS. Ann Hematol Oncol. 2015;2(8):1056.Google Scholar
  10. 10.
    Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J Clin Oncol. 2013;31:3360–8.  https://doi.org/10.1200/JCO.2012.47.4874.CrossRefPubMedGoogle Scholar
  11. 11.
    Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441–8.  https://doi.org/10.1200/JCO.2011.37.1286.CrossRefPubMedGoogle Scholar
  12. 12.
    Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival M-EM, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 2018;32:2352–62.  https://doi.org/10.1038/s41375-018-0135-8.CrossRefGoogle Scholar
  13. 13.
    Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.  https://doi.org/10.1182/blood-2016-08-733196.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122:1384–94.  https://doi.org/10.1182/blood-2013-04-496596.CrossRefPubMedGoogle Scholar
  15. 15.
    Foran JM, Sun Z, Claxton DF, Lazarus HM, Thomas ML, Melnick A, et al. North American Leukemia, Intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN Cancer Research Group (E2906). ASH Meeting Abstracts 2015;126:217–217.Google Scholar
  16. 16.
    Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, et al. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia. 2017;31:310–7.  https://doi.org/10.1038/leu.2016.225.CrossRefPubMedGoogle Scholar
  17. 17.
    Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, et al. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 2017;129:1636–45.  https://doi.org/10.1182/blood-2016-10-740613.CrossRefPubMedGoogle Scholar
  18. 18.
    Burnett AK, Hills RK, Nielsen OJ, Freeman S, Ali A, Cahalin P, et al. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 trial. Leukemia. 2018;32:2693–714.  https://doi.org/10.1038/s41375-018-0148-3.CrossRefPubMedGoogle Scholar
  19. 19.
    Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, et al. Randomized phase II study of clofarabine-based consolidation for younger adults with acute myeloid leukemia in first remission. J Clin Oncol. 2017;35:1223–30.  https://doi.org/10.1200/JCO.2016.70.4551.CrossRefPubMedGoogle Scholar
  20. 20.
    Chen EC, Fathi AT, Brunner AM. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Onco Targets Ther. 2018;11:3425–34.  https://doi.org/10.2147/OTT.S141212.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    • Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36:2684–92.  https://doi.org/10.1200/JCO.2017.77.6112. This phase III trial showed the superiority of CPX-351 compared to 7+3 chemotherapy in elderly fit patients with secondary, therapy-related or de novo AML with myelodysplastic syndrome-related abnormalities. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854–60.  https://doi.org/10.1182/blood-2013-01-466706.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31:1855–68.  https://doi.org/10.1038/leu.2017.187.CrossRefPubMedGoogle Scholar
  24. 24.
    Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34:972–9.  https://doi.org/10.1200/JCO.2015.64.0060.CrossRefPubMedGoogle Scholar
  25. 25.
    Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie J-N, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508–16.  https://doi.org/10.1016/S0140-6736(12)60485-1.CrossRefPubMedGoogle Scholar
  26. 26.
    Burnett A, Cavenagh J, Russell N, Hills R, Kell J, Jones G, et al. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica. 2016;101:724–31.  https://doi.org/10.3324/haematol.2016.141937.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Taksin A-L, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21:66–71.  https://doi.org/10.1038/sj.leu.2404434.CrossRefPubMedGoogle Scholar
  28. 28.
    • Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial. Haematologica. 2018.  https://doi.org/10.3324/haematol.2018.188888. This is an independent review of the ALFA-0701 trial which confirmed the event-free survival advantage of addition of fractionated gemtuzumab ozogamicin to intensive chemotherapy.
  29. 29.
    Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986–96.  https://doi.org/10.1016/S1470-2045(14)70281-5.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sedov V, Stuart RK. Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. Ther Adv Hematol. 2017;8:185–95.  https://doi.org/10.1177/2040620717703012.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, et al. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017;102:1709–17.  https://doi.org/10.3324/haematol.2017.168732.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16:1025–36.  https://doi.org/10.1016/S1470-2045(15)00201-6.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Assi R, Ravandi F. FLT3 inhibitors in acute myeloid leukemia: choosing the best when the optimal does not exist. Am J Hematol. 2018;93:553–63.  https://doi.org/10.1002/ajh.25027.CrossRefPubMedGoogle Scholar
  34. 34.
    Pratz KW, Levis M. How I treat FLT3-mutated AML. Blood. 2017;129:565–71.  https://doi.org/10.1182/blood-2016-09-693648.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    • Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377:454–64.  https://doi.org/10.1056/NEJMoa1614359. The RATIFY trial showed that the addition of midostaurin to intensive chemotherapy significantly prolongs overall survival in FLT3 -mutated AML. CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Larson RA, Mandrekar SJ, Sanford BL, Laumann K, Geyer SM, Bloomfield CD, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. ASH Meeting Abstract 2017;130:145–145.Google Scholar
  37. 37.
    Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691–9.  https://doi.org/10.1016/S1470-2045(15)00362-9.CrossRefPubMedGoogle Scholar
  38. 38.
    Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121:4655–62.  https://doi.org/10.1182/blood-2013-01-480228.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Rautenberg C, Nachtkamp K, Dienst A, Schmidt PV, Heyn C, Kondakci M, et al. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. Eur J Haematol. 2017;98:348–54.  https://doi.org/10.1111/ejh.12832.CrossRefPubMedGoogle Scholar
  40. 40.
    Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3 -ITD mutated acute myeloid leukemia. Am J Hematol. 2018;93:1136–41.  https://doi.org/10.1002/ajh.25198.CrossRefPubMedGoogle Scholar
  41. 41.
    Chen Y-B, Li S, Lane AA, Connolly C, Del Rio C, Valles B, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20:2042–8.  https://doi.org/10.1016/j.bbmt.2014.09.007.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3 -ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175:496–504.  https://doi.org/10.1111/bjh.14260.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia: sorafenib after HSCT for FLT3-mutated AML. Cancer. 2017;123:2867–74.  https://doi.org/10.1002/cncr.30680.CrossRefPubMedGoogle Scholar
  44. 44.
    Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19:889–903.  https://doi.org/10.1016/S1470-2045(18)30240-7.CrossRefPubMedGoogle Scholar
  45. 45.
    Cortes J, Khaled S, Martinelli G, Perl AE, Ganguly S, et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication–mutated (mut) relapsed/refractory AML in the phase 3, randomized, controlled quantum-R trial. EHA Meeting Abstracts 2018, 218882 https://learningcenter.ehaweb.org/eha/2018/stockholm/218882/jorge.cortes.quizartinib.significantly.prolongs.overall.survival.in.patients.html.
  46. 46.
    Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, et al. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017;130:48–58.  https://doi.org/10.1182/blood-2016-04-711820.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18:1061–75.  https://doi.org/10.1016/S1470-2045(17)30416-3.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Iida H, Morita S, et al. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: an open-label phase 1 study. Cancer Sci. 2018;109:3235–44.  https://doi.org/10.1111/cas.13749.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, et al. A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018;2:825–31.  https://doi.org/10.1182/bloodadvances.2018015925.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Cortes JE, Kantarjian HM, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Daver NG, Pemmaraju N, Jabbour E, Estrov Z, Ramachandran A, Paradela J, Pond B, Ravandi F, Vusirikala M, Patel PA, Levis MJ, Perl AE, Andreeff M, Collins R Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. ASCO Meeting Abstracts 2016;34:7008–7008.  https://doi.org/10.1200/JCO.2016.34.15_suppl.7008.
  51. 51.
    Nassereddine S, Lap CJ, Haroun F, Tabbara I. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Ann Hematol. 2017;96:1983–91.  https://doi.org/10.1007/s00277-017-3161-0.CrossRefPubMedGoogle Scholar
  52. 52.
    • Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–31.  https://doi.org/10.1182/blood-2017-04-779405. This large phase I/II trial evaluated enasidenib in IDH2-mutated relapsed/refractory AML, showing an overall response rate of 40%, and a prolonged duration of response in patients achieving complete remission. CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130:732–41.  https://doi.org/10.1182/blood-2017-04-779447.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018;559:125–9.  https://doi.org/10.1038/s41586-018-0251-7.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018;24:1167–77.  https://doi.org/10.1038/s41591-018-0115-6.CrossRefPubMedGoogle Scholar
  56. 56.
    • DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386–98.  https://doi.org/10.1056/NEJMoa1716984. Ivosidenib efficacy was demonstrated in this large phase I dose escalation and dose-expansion study including IDH1 -mutated relapsed/refractory AML patients. CrossRefPubMedGoogle Scholar
  57. 57.
    DiNardo CD, Stein AS, Stein EM, Fathi AT, Schuh AC, Montesinos Fernández P, et al. Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). ASCO Meeting Abstracts 2018;36:7042–7042.  https://doi.org/10.1200/JCO.2018.36.15_suppl.7042.
  58. 58.
    Bykov VJN, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol. 2016;6:21.  https://doi.org/10.3389/fonc.2016.00021.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Sallman D, Dezern A, Sweet K, Steensma D, Cluzeau T, Sekeres M, et al. Phase 1b/2 combination study of APR-246 and azacitidine (aza) in patients with tp53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). EHA Meeting Abstracts 2018, 214477 https://learningcenter.ehaweb.org/eha/2018/stockholm/214477/david.sallman.phase.1b.2.combination.study.of.apr246.and.azacitidine.28aza29.in.html?f=media=1
  60. 60.
    Cortes JE, Heidel FH, Heuser M, Fiedler W, Smith BD, Robak T, et al. A phase 2 randomized study of low dose Ara-C with or without Glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. ASH Meeting Abstracts 2016;128:99–99.Google Scholar
  61. 61.
    Martinelli G, Pappayannidis C, Yee K, Vey N, Drummond M, Kelly K, et al. Phase 1b results of idasanutlin + cytarabine (ara-c) in acute myeloid leukemia (AML) patients (pts). EHA Meeting Abstracts 2018, 135260 https://learningcenter.ehaweb.org/eha/2018/stockholm/214477/david.sallman.phase.1b.2.combination.study.of.apr246.and.azacitidine.28aza29.in.html?f=media=1
  62. 62.
    DeAngelo DJ, Jonas BA, Liesveld J, O’Dwyer M, Bixby D, Advani AS, et al. GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML. ASCO Meeting Abstracts 2017;35: 2520–2520.  https://doi.org/10.1200/JCO.2017.35.15_suppl.2520.
  63. 63.
    Bhatnagar B, Walker AR, Mims AS, Vasu S, Klisovic RB, Behbehani G, Blachly JS, Larkin KTM, Long M, Zhao Q, Ranganathan P, Byrd JC, Blum WG, Garzon R Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia. ASCO Meeting Abstracts. 2018;36: 7048–7048.  https://doi.org/10.1200/JCO.2018.36.15_suppl.7048.
  64. 64.
    Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, et al. Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. Blood Adv. 2018;2:381–9.  https://doi.org/10.1182/bloodadvances.2017013391.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Fröhling S, Agrawal M, Jahn N, Fransecky LR, Baldus CD, Wäsch R, et al. CDK4/6 inhibitor palbociclib for treatment of KMT2A-rearranged acute myeloid leukemia: interim analysis of the AMLSG 23-14 trial. ASH Meeting Abstracts. 2016;128:1608–1608.Google Scholar
  66. 66.
    Walker AR, Bhatnagar B, Marcondes AMQ, DiPaolo J, Vasu S, Mims AS, et al. Interim results of a phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with chemotherapy in patients with acute myeloid leukemia. ASH Meeting Abstracts. 2016;128:2831–2831.Google Scholar
  67. 67.
    Byrne M, Donnellan W, Patel MR, Zeidan AM, Cherry M, Baer MR, et al. Preliminary results from an ongoing phase 1/2 study of INCB053914, a pan-proviral integration sites for moloney virus (PIM) kinase inhibitor, in patients with advanced hematologic malignancies. ASH Meeting Abstracts. 2017;130:2585–2585.Google Scholar
  68. 68.
    Garcia-Manero G, Yang H, Fang Z, Kantarjian HM, DiNardo CD, Jabbour EJ, et al. Phase 1 results of FF-10501-01, a novel inosine 5’-monophosphate dehydrogenase inhibitor, in advanced acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), including hypomethylating agent (HMA) failures. ASH Meeting Abstracts. 2016;128:1640–1640.Google Scholar
  69. 69.
    Letai A. Functional precision cancer medicine—moving beyond pure genomics. Nat Med. 2017;23:1028–35.  https://doi.org/10.1038/nm.4389.CrossRefPubMedGoogle Scholar
  70. 70.
    Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018;132:1007–12.  https://doi.org/10.1182/blood-2018-03-828269.CrossRefPubMedGoogle Scholar
  71. 71.
    Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106–17.  https://doi.org/10.1158/2159-8290.CD-16-0313.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Wei A, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL, et al. Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes. Blood. 2017;130:890.CrossRefGoogle Scholar
  73. 73.
    DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216–28.  https://doi.org/10.1016/S1470-2045(18)30010-X.CrossRefPubMedGoogle Scholar
  74. 74.
    • DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Blood. 2018.  https://doi.org/10.1182/blood-2018-08-868752. In this large phase Ib study in newly diagnosed elderly AML patients, venetoclax combined with hypomethylating agents led to a high remission rate and an overall survival higher than expected in this population.
  75. 75.
    DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401–7.  https://doi.org/10.1002/ajh.25000.CrossRefPubMedGoogle Scholar
  76. 76.
    Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103:e404–7.  https://doi.org/10.3324/haematol.2018.188094.
  77. 77.
    Teh T-C, Nguyen N-Y, Moujalled DM, Segal D, Pomilio G, Rijal S, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia. 2018;32:303–12.  https://doi.org/10.1038/leu.2017.243.CrossRefPubMedGoogle Scholar
  78. 78.
    Glass J, Hassane DC, Wouters B, Kunimoto H, Avellino R, Garrett-Bakelman FE, et al. Epigenetic identity in AML depends on disruption of non-promoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers. Cancer Discov. 2017:CD-16-1032.  https://doi.org/10.1158/2159-8290.CD-16-1032.
  79. 79.
    Ritchie EK, Feldman EJ, Christos PJ, Rohan SD, Lagassa CB, Ippoliti C, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54:2003–7.  https://doi.org/10.3109/10428194.2012.762093.CrossRefPubMedGoogle Scholar
  80. 80.
    Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–36.  https://doi.org/10.1056/NEJMoa1605949.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia TM, Huang X, et al. Randomized phase II trial of two schedules of decitabine as frontline therapy in elderly patients with acute myeloid leukemia ineligible for standard cytotoxic induction regimens. Blood. 2016;128:1612.CrossRefGoogle Scholar
  82. 82.
    Huls G, Chitu D, Havelange V, Jongen-Lavrencic M, Loosdrecht A van de, Biemond BJ, et al. Randomized maintenance therapy with azacitidine (vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). results of the HOVON97 phase III randomized multicentre study (EudraCT 2008-001290-15). ASH Meeting Abstracts 2017;130:463–463.Google Scholar
  83. 83.
    Rashidi A, Walter RB, Tallman MS, Appelbaum FR, DiPersio JF. Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. Blood. 2016;128:763–73.  https://doi.org/10.1182/blood-2016-03-674127.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Cornelissen JJ, Norden Y van, Gelder M van, Breems DA, Maertens J, Jongen-Lavrencic M, et al. Early post-transplant epigenetic therapy by panobinostat and decitabine followed by donor lymphocyte infusion (DLI): interim results of the HOVON-116 phase I/II feasibility study in poor-risk AML recipients of allogeneic stem cell transplantation (alloHSCT). ASH Meeting Abstracts. 2016;128:832–832.Google Scholar
  85. 85.
    Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29:2521–7.  https://doi.org/10.1200/JCO.2010.34.4226.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O’Connell CL, Tibes R, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017;18:1317–26.  https://doi.org/10.1016/S1470-2045(17)30576-4.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O’Connell CL, Griffiths EA, et al. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia: activity and safety of Guadecitabine in AML. Cancer. 2018;124:325–34.  https://doi.org/10.1002/cncr.31138.CrossRefPubMedGoogle Scholar
  88. 88.
    Hansen R. Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy – Astex Available: https://astx.com/astex-pharmaceuticals-and-otsuka-announce-results-of-the-phase-3-astral-1-study-of-guadecitabine-sgi-110-in-treatment-naive-aml-patients-ineligible-to-receive-intense-induction-chemotherapy/
  89. 89.
    Schuh AC, Döhner H, Pleyer L, Seymour JF, Fenaux P, Dombret H. Azacitidine in adult patients with acute myeloid leukemia. Crit Rev Oncol Hematol. 2017;116:159–77.  https://doi.org/10.1016/j.critrevonc.2017.05.010.CrossRefPubMedGoogle Scholar
  90. 90.
    Manero GG, Atallah E, Khaled SK, Arellano M, Patnaik MM, Odenike O, et al. A phase 2 study of pracinostat and azacitidine in elderly patients with acute myeloid leukemia (AML) not eligible for induction chemotherapy: response and long-term survival benefit. ASH Meeting Abstracts. 2016;128:100–100.Google Scholar
  91. 91.
    Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018;131:1415–24.  https://doi.org/10.1182/blood-2017-09-805895.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016;3:e186–95.  https://doi.org/10.1016/S2352-3026(15)00247-1.CrossRefGoogle Scholar
  93. 93.
    Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018;131:2661–9.  https://doi.org/10.1182/blood-2017-12-818948.CrossRefPubMedGoogle Scholar
  94. 94.
    Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, et al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia. 2018;32:1621–30.  https://doi.org/10.1038/s41375-018-0129-6.CrossRefPubMedGoogle Scholar
  95. 95.
    Hills RK, Burnett AK. Applicability of a “Pick a Winner” trial design to acute myeloid leukemia. Blood. 2011;118:2389–94.  https://doi.org/10.1182/blood-2011-02-337261.CrossRefPubMedGoogle Scholar
  96. 96.
    Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526–31.  https://doi.org/10.1038/s41586-018-0623-z.CrossRefPubMedGoogle Scholar
  97. 97.
    Beyar-Katz O, Gill S. Novel approaches to acute myeloid leukemia immunotherapy. Clin Cancer Res. 2018;24:5502–15.  https://doi.org/10.1158/1078-0432.CCR-17-3016.CrossRefPubMedGoogle Scholar
  98. 98.
    Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49:332–40.  https://doi.org/10.1038/ng.3756.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hematology, Hopital Saint-Louis, Assistance Publique Hopitaux de ParisParis Diderot UniversityParisFrance
  2. 2.Department of HematologyUniversità degli studi di TorinoTurinItaly
  3. 3.INSERM/CNRS UMR 944/7212, Paris Cancer Research Institute (PACRI)ParisFrance
  4. 4.INSERM/CNRS UMR 944/7212, Hematology Department, Hopital Saint-Louis, Hopitaux de ParisUniversite Paris DiderotParisFrance

Personalised recommendations